Phase III randomized double-blind placebo-controlled multi-centre study assessing the efficacy and safety of durvalumab versus placebo as treatment following SBRT in patients with Stage I/II non small cell lung cancer.

Brief description of study

The purpose of this study by AstraZeneca AB is to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy.

Clinical Study Identifier: s19-00223 Identifier: NCT03833154

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.